Budget 2018-19

  Omicron was first detected in southern Africa last month and has triggered global alarm as governments fear another surge in infections South Africa is preparing its hospitals for more admissions, as the  Omicron coronavirus variant  pushes the country into a fourth wave of COVID-19 cases, President Cyril Ramaphosa said on Monday. Omicron was first detected in southern Africa last month and has triggered global alarm as governments fear another surge in infections. South Africa’s daily infections surged last week to more than 16,000 on Friday from roughly 2,300 on Monday. Ramaphosa said in a weekly newsletter that Omicron appeared to be dominating new cases in most of the country’s nine provinces and urged more people to get vaccinated against COVID-19. “ South Africa  now has sufficient supplies of vaccines, …vaccination is essential for our economic recovery because as more people are vaccinated more areas of economic activity will be opened up,” he said. The gov...

  Indonesia will at the first phase provide the Covid-19 vaccine to 9.1 million people between November and December 2020 Indonesia will at the first phase provide the COVID-19 vaccine to 9.1 million people between November and December 2020, the Health Ministry’s Disease Control and Prevention Director General Achmad Yurianto said. The first phase of vaccination will be carried out on the groups of people with highest risk of COVID-19 infections, namely medical and public service workers including airport employees, soldiers and police personnel, Xinhua news agency reported on Monday. Yurianto said that the vaccine would only be given to people aged between 18 years old and 59 years old, because clinical trials of vaccine candidates in the world have yet to target categories outside that age range. The vaccination will be carried out after the Indonesian Drug and Food Supervisory Agency (BPOM) issues an emergency use authorization and the Indonesian Ulema Council (MUI) provides ha...

  Takeda Pharmaceutical said an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for Covid-19 after months of regulatory delays TOKYO (Reuters) – Japan’s Takeda Pharmaceutical Co said on Friday an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID-19 after months of regulatory delays. The phase 3 trial by the group, known as the CoVIg Plasma Alliance, aims to enroll 500 adult patients from the United States, Mexico and 16 other countries, according to a statement. Patients will be treated with Gilead Science Inc’s Remdesivir alongside the  plasma treatment , which will be provided by CSL Behring, Takeda and two other companies. “We are hopeful that data from the clinical trial will be available before the end of the year,” Bill Mezzanotte, chief medical officer of CSL Behring, said in the release. The group had aimed to beg...